Logo image of LIFE

ATYR PHARMA INC (LIFE) Stock Fundamental Analysis

NASDAQ:LIFE - Nasdaq - US0021202025 - Common Stock - Currency: USD

1.9  +0.05 (+2.7%)

After market: 1.94 +0.04 (+2.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LIFE. LIFE was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of LIFE have multiple concerns. While showing a medium growth rate, LIFE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LIFE has reported negative net income.
In the past year LIFE has reported a negative cash flow from operations.
In the past 5 years LIFE always reported negative net income.
In the past 5 years LIFE always reported negative operating cash flow.
LIFE Yearly Net Income VS EBIT VS OCF VS FCFLIFE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

LIFE's Return On Assets of -47.62% is in line compared to the rest of the industry. LIFE outperforms 49.74% of its industry peers.
LIFE's Return On Equity of -63.85% is in line compared to the rest of the industry. LIFE outperforms 58.06% of its industry peers.
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROIC N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
LIFE Yearly ROA, ROE, ROICLIFE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LIFE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIFE Yearly Profit, Operating, Gross MarginsLIFE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

LIFE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LIFE has more shares outstanding
The number of shares outstanding for LIFE has been increased compared to 5 years ago.
LIFE has a worse debt/assets ratio than last year.
LIFE Yearly Shares OutstandingLIFE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
LIFE Yearly Total Debt VS Total AssetsLIFE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

LIFE has an Altman-Z score of -4.12. This is a bad value and indicates that LIFE is not financially healthy and even has some risk of bankruptcy.
LIFE has a worse Altman-Z score (-4.12) than 61.18% of its industry peers.
LIFE has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, LIFE is in line with its industry, outperforming 44.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACC8.87%
LIFE Yearly LT Debt VS Equity VS FCFLIFE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

LIFE has a Current Ratio of 6.07. This indicates that LIFE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LIFE (6.07) is better than 60.66% of its industry peers.
A Quick Ratio of 6.07 indicates that LIFE has no problem at all paying its short term obligations.
LIFE's Quick ratio of 6.07 is fine compared to the rest of the industry. LIFE outperforms 61.01% of its industry peers.
Industry RankSector Rank
Current Ratio 6.07
Quick Ratio 6.07
LIFE Yearly Current Assets VS Current LiabilitesLIFE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.93% over the past year.
Looking at the last year, LIFE shows a very negative growth in Revenue. The Revenue has decreased by -94.34% in the last year.
Measured over the past years, LIFE shows a very negative growth in Revenue. The Revenue has been decreasing by -67.68% on average per year.
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LIFE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.04% yearly.
LIFE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 291.57% yearly.
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LIFE Yearly Revenue VS EstimatesLIFE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
LIFE Yearly EPS VS EstimatesLIFE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

LIFE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LIFE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIFE Price Earnings VS Forward Price EarningsLIFE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIFE Per share dataLIFE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

LIFE's earnings are expected to grow with 26.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.08%
EPS Next 3Y26.27%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIFE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATYR PHARMA INC

NASDAQ:LIFE (6/4/2024, 8:12:25 PM)

After market: 1.94 +0.04 (+2.11%)

1.9

+0.05 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-02 2024-05-02/amc
Earnings (Next)08-07 2024-08-07/amc
Inst Owners69.81%
Inst Owner Change0.13%
Ins Owners12.06%
Ins Owner Change0%
Market Cap129.87M
Analysts81.82
Price Target25.09 (1220.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.74%
Min EPS beat(2)-2.98%
Max EPS beat(2)4.45%
EPS beat(4)3
Avg EPS beat(4)9.32%
Min EPS beat(4)-2.98%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)12.77%
EPS beat(12)7
Avg EPS beat(12)6.02%
EPS beat(16)10
Avg EPS beat(16)4.78%
Revenue beat(2)1
Avg Revenue beat(2)475.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)1051.96%
Revenue beat(4)1
Avg Revenue beat(4)193.76%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)2
Avg Revenue beat(8)641.07%
Revenue beat(12)2
Avg Revenue beat(12)394.04%
Revenue beat(16)4
Avg Revenue beat(16)382.04%
PT rev (1m)8.85%
PT rev (3m)10.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.98%
EPS NY rev (1m)2.81%
EPS NY rev (3m)-7.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-84.63%
Revenue NY rev (3m)-95.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 220.87
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.01
BVpS1.24
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.62%
ROE -63.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 432.17%
Cap/Sales 507.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.07
Quick Ratio 6.07
Altman-Z -4.12
F-Score1
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)486.58%
Cap/Depr(5y)301.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.69%
EPS Next Y2.52%
EPS Next 2Y9.08%
EPS Next 3Y26.27%
EPS Next 5Y35.04%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-19.38%
Revenue Next 2Y375.78%
Revenue Next 3Y505.83%
Revenue Next 5Y291.57%
EBIT growth 1Y-25.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.85%
EBIT Next 3Y43.39%
EBIT Next 5Y48.12%
FCF growth 1Y-54.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.21%
OCF growth 3YN/A
OCF growth 5YN/A